Kenvue Inc. KVUE
Composite 57/100; the shares have moved about 22% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 48/100 — a slight mark against it.
Income ranks 80/100 — a strong point in its favour. Growth ranks 63/100 — a moderate point in its favour. Quality ranks 62/100 — a slight point in its favour.
Valuation ranks 48/100 — a slight mark against it. Balance-sheet strength ranks 49/100 — a slight mark against it.
What the company does Kenvue Inc. (KVUE) is a global consumer health company with three segments: Self Care, Skin Health and Beauty, and Essential Health. Its portfolio includes over-the-counter medicines (e.g., Tylenol, Zyrtec), skincare brands (e.g., Neutrogena, Aveeno), and essential health products (e.g., Listerine, Band-Aid). The company operates in 160+ countries under 40+ brands.
Key financials Kenvue reports ROE 15.6%, ROA 7.0%, and ROCE 12.5%. Gross margin is 58.4% with operating and net margins at 19.4% and 10.8%, respectively. Revenue declined -2.1% year-over-year, but EPS grew 42.6%. Dividend yield is 4.4% with a payout ratio of 70.7%.
Stock health The stock shows mixed momentum: +12.79% over 3 months, +3.69% over 6 months, and -4.97% over 12 months. It is -8.21% below its 52-week high, with RSI(14) at 53.40. Beta is 0.43, indicating lower volatility relative to the market.
Price vs fair value KVUE trades at a **discount of 1.90%** versus the analyst mean target of 19.50. - Forward P/E of 16.56 is below the trailing P/E of 22.59 (Valuation anchor). - Sideravia’s Valuation score of 47.7/100 aligns with the discount. - Income score of 80.0 supports the dividend yield of 4.4%. - Growth score of 64.4 contrasts with the -2.1% revenue decline.
Looking forward Forward PEG of 0.45 suggests potential value relative to growth. Analysts may weigh the -2.1% revenue decline against the 42.6% EPS growth and strong profitability metrics. Momentum trends and valuation scores indicate a balanced risk-reward profile.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.